Nanotechnology Now







Heifer International

Wikipedia Affiliate Button


DHgate

Home > Press > Stellar Biotechnologiesí Exclusive License Agreement on Bayer Innovations/Stellar KLH Technology

Abstract:
Stellar Biotechnologies, Inc. (TSX-V: KLH) (PINKSHEETS: SBOTF) is pleased to announce that it has acquired an exclusive, irrevocable, worldwide, sub-licensable and royalty-free license to the technology developed through a Collaborative Research Agreement between Stellar and Bayer Innovations (BIG).

Stellar Biotechnologiesí Exclusive License Agreement on Bayer Innovations/Stellar KLH Technology

Port Hueneme, CA | Posted on December 7th, 2010

The license includes a carve-out by BIG for use of the technology in its non-Hodgkin lymphoma (NHL) vaccine which is currently under development. Otherwise, the license leaves Stellar free to commercialize the technology, exclusively, in all other fields.

Stellar CEO, Frank Oakes said, "The technology developed through the collaboration with BIG represents a breakthrough in the production of highly characterized, immunogenically potent carrier proteins (ICPs), not only in terms of quality and purity, but also for cost management in the final drug product. The technology will be integrated into BIG's NHL vaccine platform, and commercialized broadly by Stellar for other vaccines and related products."

Stellar's CEO letter to shareholders, dated 11/24/10, has been posted:

www.stellarbiotechnologies.com/investors/shareholders/index.php?&content_id=54

There can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Readers should not place undue reliance on such statements. Except in accordance with applicable securities laws, the Company expressly disclaims any obligation to update any forward-looking statements or forward-looking statements that are incorporated by reference herein. This news release does not constitute an offer to sell, or a solicitation of an offer to buy any of the Company's securities set out herein in the United States, or to, or for the benefit or account of, a U.S. Person or person in the United States. Neither TSX Venture Exchange nor its Regulation Services Provider accepts responsibility for the adequacy or accuracy of these releases.

####

About Stellar Biotechnologies
Stellar Biotechnologies, Inc. (TSX-V: KLH) (PINKSHEETS: SBOTF) is a world leader in sustainable manufacturing of pharmaceutical grade immune carrier proteins (ICP), particularly with regard to the present most important pharmaceutical protein in this class, KLH (Keyhole Limpet Hemocyanin). This evolutionary protein has a highly complex structure that makes it ideal for use in human and animal vaccines and diagnostic products. With partners and customers, its flagship Stellar KLH products are in the clinic, and on the way to being established as the only sustainable, long-term pharmaceutical source.

For more information, please click here

Contacts:
Darrell Brookstein

Copyright © Stellar Biotechnologies

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

News and information

Quantum teleportation on a chip: A significant step towards ultra-high speed quantum computers April 1st, 2015

So, near and yet so far: Stable HGNs for Raman April 1st, 2015

Two-dimensional dirac materials: Structure, properties, and rarity April 1st, 2015

3-D neural structure guided with biocompatible nanofiber scaffolds and hydrogels April 1st, 2015

Nanomedicine

A novel way to apply drugs to dental plaque Nanoparticles release drugs to reduce tooth decay April 1st, 2015

3-D neural structure guided with biocompatible nanofiber scaffolds and hydrogels April 1st, 2015

Nanion Technologies Appoints James Costantin as Director of Customer Relations: Nanion is pleased to announce the appointment of Dr. James Costantin as Director of Customer Relations at Nanion Technologies Inc. March 31st, 2015

Prototype 'nanoneedles' generate new blood vessels in mice: Scientists have developed tiny 'nanoneedles' that have successfully prompted parts of the body to generate new blood vessels, in a trial in mice March 31st, 2015

Announcements

Quantum teleportation on a chip: A significant step towards ultra-high speed quantum computers April 1st, 2015

So, near and yet so far: Stable HGNs for Raman April 1st, 2015

Two-dimensional dirac materials: Structure, properties, and rarity April 1st, 2015

3-D neural structure guided with biocompatible nanofiber scaffolds and hydrogels April 1st, 2015

Patents/IP/Tech Transfer/Licensing

From tobacco to cyberwood March 31st, 2015

Roll up your screen and stow it away? Tel Aviv University researchers develop molecular backbone of super-slim, bendable digital displays March 30th, 2015

Novel nanoparticle therapy promotes wound healing March 27th, 2015

New processing technology converts packing peanuts to battery components March 22nd, 2015

Nanobiotechnology

3-D neural structure guided with biocompatible nanofiber scaffolds and hydrogels April 1st, 2015

From tobacco to cyberwood March 31st, 2015

Wrapping carbon nanotubes in polymers enhances their performance: Scientists at Japan's Kyushu University say polymer-wrapped carbon nanotubes hold much promise in biotechnology and energy applications March 30th, 2015

'Atomic chicken-wire' is key to faster DNA sequencing March 30th, 2015

NanoNews-Digest
The latest news from around the world, FREE




  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoTech-Transfer
University Technology Transfer & Patents
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More










ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project







© Copyright 1999-2015 7th Wave, Inc. All Rights Reserved PRIVACY POLICY :: CONTACT US :: STATS :: SITE MAP :: ADVERTISE